Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
JAMA Surg ; 154(8): 706-714, 2019 08 01.
Article in English | MEDLINE | ID: mdl-31141112

ABSTRACT

Importance: Ampullary adenocarcinoma is a rare malignant neoplasm that arises within the duodenal ampullary complex. The role of adjuvant therapy (AT) in the treatment of ampullary adenocarcinoma has not been clearly defined. Objective: To determine if long-term survival after curative-intent resection of ampullary adenocarcinoma may be improved by selection of patients for AT directed by histologic subtype. Design, Setting, and Participants: This multinational, retrospective cohort study was conducted at 12 institutions from April 1, 2000, to July 31, 2017, among 357 patients with resected, nonmetastatic ampullary adenocarcinoma receiving surgery alone or AT. Cox proportional hazards regression was used to identify covariates associated with overall survival. The surgery alone and AT cohorts were matched 1:1 by propensity scores based on the likelihood of receiving AT or by survival hazard from Cox modeling. Overall survival was compared with Kaplan-Meier estimates. Exposures: Adjuvant chemotherapy (fluorouracil- or gemcitabine-based) with or without radiotherapy. Main Outcomes and Measures: Overall survival. Results: A total of 357 patients (156 women and 201 men; median age, 65.8 years [interquartile range, 58-74 years]) underwent curative-intent resection of ampullary adenocarcinoma. Patients with intestinal subtype had a longer median overall survival compared with those with pancreatobiliary subtype (77 vs 54 months; P = .05). Histologic subtype was not associated with AT administration (intestinal, 52.9% [101 of 191]; and pancreatobiliary, 59.5% [78 of 131]; P = .24). Patients with pancreatobiliary histologic subtype most commonly received gemcitabine-based regimens (71.0% [22 of 31]) or combinations of gemcitabine and fluorouracil (12.9% [4 of 31]), whereas treatment of those with intestinal histologic subtype was more varied (fluorouracil, 50.0% [17 of 34]; gemcitabine, 44.1% [15 of 34]; P = .01). In the propensity score-matched cohort, AT was not associated with a survival benefit for either histologic subtype (intestinal: hazard ratio, 1.21; 95% CI, 0.67-2.16; P = .53; pancreatobiliary: hazard ratio, 1.35; 95% CI, 0.66-2.76; P = .41). Conclusions and Relevance: Adjuvant therapy was more frequently used in patients with poor prognostic factors but was not associated with demonstrable improvements in survival, regardless of tumor histologic subtype. The value of a multimodality regimen remains poorly defined.


Subject(s)
Adenocarcinoma/therapy , Ampulla of Vater/pathology , Common Bile Duct Neoplasms/therapy , Deoxycytidine/analogs & derivatives , Fluorouracil/therapeutic use , Neoplasm Staging , Propensity Score , Adenocarcinoma/diagnosis , Adenocarcinoma/mortality , Aged , Antimetabolites, Antineoplastic/therapeutic use , Chemoradiotherapy, Adjuvant , Combined Modality Therapy , Common Bile Duct Neoplasms/diagnosis , Common Bile Duct Neoplasms/mortality , Deoxycytidine/therapeutic use , Female , Follow-Up Studies , Humans , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Pancreaticoduodenectomy , Prognosis , Retrospective Studies , Survival Rate/trends , United States/epidemiology , Gemcitabine
2.
J Gastrointest Surg ; 20(5): 914-23, 2016 05.
Article in English | MEDLINE | ID: mdl-26850262

ABSTRACT

BACKGROUND: Delayed gastric emptying (DGE) is a common complication of pancreaticoduodenectomy. We determined the efficiency of a new reconstruction technique, designed to preserve motilin-secreting cells and maximize the utility of their receptors, in reducing the incidence of DGE after pancreaticoduodenectomy. METHODS: From April 2005 to September 2014, 217 consecutive patients underwent pancreaticoduodenectomy at our institution. Nine patients who underwent total pancreatectomy were excluded. We compared outcomes between patients who underwent pancreaticoduodenectomy with resection of the pyloric ring followed by proximal Roux-en-y gastrojejunal anastomosis (group I, n = 90) and patients who underwent standard pancreaticoduodenectomy with the orthotopic reconstruction technique (group II, n = 118). RESULTS: Overall and clinically relevant rates of DGE were significantly lower in group I than in group II (10 and 2.2 % vs. 57 and 24 %, respectively; p < 0.05). Length of hospital stay as a result of DGE was shorter in group I than in group II. In univariate analysis, older age, comorbidities, ASA grade 4, operative time, preoperative diabetes, standard reconstruction technique, and postoperative complications were significant risk factors for DGE. In multivariate analysis, older age, standard technique, and postoperative complications were independent risk factors for DGE. CONCLUSION: Our new reconstruction technique reduces the occurrence of DGE after pancreaticoduodenectomy.


Subject(s)
Anastomosis, Roux-en-Y/adverse effects , Gastric Emptying , Gastroparesis/surgery , Jejunum/surgery , Pancreaticoduodenectomy/adverse effects , Pylorus/surgery , Stomach/surgery , Adult , Aged , Aged, 80 and over , Female , Gastroparesis/etiology , Gastroparesis/physiopathology , Humans , Male , Middle Aged , Pilot Projects , Prospective Studies , Pyloric Antrum/surgery , Pylorus/physiopathology , Stomach/physiopathology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL